NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
STIM
Neuronetics, Inc.
STIM has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STIM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
STIM's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
STIM PE Valuation
STIM has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
STIM has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over STIM on earnings quality, reporting a profit while its opponent remains loss making.
STIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.33 | +$0.50 |
| Q2 2026 | -$0.44 | +$0.70 |
| Q1 2026 | -$0.54 | +$0.78 |
| Q4 2025 | -$0.59 | +$0.79 |
| Q3 2025 | -$0.83 | +$0.38 |
| Q2 2025 | -$1.14 | -$0.04 |
| Q1 2025 | -$1.32 | -$0.38 |
| Q4 2024 | -$1.38 | -$0.33 |
STIM is still losing money, but far less than before: $0.33 per share over the past year, against $1.87 at its worst in mid-2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over STIM on profitability, with a higher operating margin.
STIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42M | +13% |
| Q2 2026 | $41.6M | +9.1% |
| Q1 2026 | $34.5M | +7.8% |
| Q4 2025 | $41.8M | +86% |
| Q3 2025 | $37.3M | +101% |
| Q2 2025 | $38.1M | +132% |
| Q1 2025 | $32M | +84% |
| Q4 2024 | $22.5M | +11% |
STIM has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.3% | +21 points |
| Q2 2026 | -3.6% | +18 points |
| Q1 2026 | -26% | +8.3 points |
| Q4 2025 | -12% | +39 points |
| Q3 2025 | -20% | +22 points |
| Q2 2025 | -21% | +31 points |
| Q1 2025 | -34% | +4.9 points |
| Q4 2024 | -51% | -29 points |
STIM's operating margin was 1.3% last quarter, up 21 points from the same quarter a year ago, near the top of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over STIM on cash generation, producing positive trailing cash flow while its opponent burns cash.
STIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $768K | +$1.7M |
| Q2 2026 | -$1.4M | +$2.3M |
| Q1 2026 | -$9.6M | +$7.6M |
| Q4 2025 | $692K | +$9.4M |
| Q3 2025 | -$899K | +$4.9M |
| Q2 2025 | -$3.8M | +$1.8M |
| Q1 2025 | -$17.2M | -$4.8M |
| Q4 2024 | -$8.7M | -793% |
STIM has burned cash in almost every quarter: −$10M over the past year, against −$31M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STIM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.3% | +3.9M shares |
| 1 year | +14% | +9.7M shares |
| 3 years | +169% | +48.4M shares |
| 5 years | +197% | +51.1M shares |
| Available history | +313% | +58.4M shares |
STIM has 77M diluted shares, up 14% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STIM Net Leverage
STIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 17.8 | Oversold |
STIM's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STIM PE vs Healthcare Sector
STIM has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over STIM on trend strength, trading above more of its moving averages.
STIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.11 | 32% below |
| 20 week MA | $2.29 | 38% below |
| 50 week MA | $1.82 | 21% below |
| 100 week MA | $2.57 | 44% below |
| 200 week MA | $2.47 | 42% below |
STIM is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
STIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.50 | $10.7 | +137% |
| 2021 | $10.7 | $4.60 | -57% |
| 2022 | $4.60 | $5.97 | +30% |
| 2023 | $5.97 | $2.90 | -51% |
| 2024 | $2.90 | $1.48 | -49% |
| 2025 | $1.48 | $1.42 | -4.1% |
| 2026 YTD | $1.42 | $1.43 | +0.7% |
STIM has the edge over NVO on returns for 2026, with the stronger performance.